0
Correspondence |

Cardiac Biomarkers in Community-Acquired Pneumonia FREE TO VIEW

Stephanie Parks Taylor, MD; Brice Taylor, MD
Author and Funding Information

FINANCIAL/NONFINANCIAL DISCLOSURES: None declared.

CORRESPONDENCE TO: Stephanie Parks Taylor, MD, Department of Internal Medicine, Pulmonary and Critical Care Medicine, 1000 Blythe Blvd, Carolinas Medical Center, Charlotte, NC 28203


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(2):603. doi:10.1016/j.chest.2015.10.064
Text Size: A A A
Published online

The article “Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies” by Feldman and Anderson was an excellent and clinically relevant review of the pathogenesis and therapeutic implications of acute cardiac events in pneumonia. An important addition to the otherwise comprehensive work might have been discussion of the role of cardiac biomarkers in the prediction of mortality in patients with community-acquired pneumonia (CAP). Several natriuretic peptides, neurohormones that are released in response to cardiac stress, have been associated with higher risk of poor outcomes in CAP. These include B-type natriuretic peptide,, N-terminal pro B-type natriuretic peptide, and midregional pro-atrial natriuretic peptide. A recent study found that the natriuretic peptides provided increased discrimination when added to the Pneumonia Severity Index compared with the Pneumonia Severity Index alone, and were especially useful in identifying patients at high risk for mortality. The predictive value of these cardiac biomarkers further illustrate the important interplay between cardiac stress and mortality in CAP.

References

Feldman C. .Anderson R. . Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. Chest. 2015;148:523-532 [PubMed]journal. [CrossRef] [PubMed]
 
Mueller C. .Laule-Kilian K. .Scholer A. .Perruchoud A.P. . B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med. 2005;258:391-393 [PubMed]journal. [CrossRef] [PubMed]
 
Christ-Crain M. .Breidthardt T. .Stolz D. .et al Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med. 2008;264:166-176 [PubMed]journal. [CrossRef] [PubMed]
 
Jeong K.Y. .Kim K. .Kim T.Y. .et al Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J. 2011;28:122-127 [PubMed]journal. [CrossRef] [PubMed]
 
Krüger S. .Ewig S. .Kunde J. .Hartmann O. .Suttorp N. .Welte T. . CAPNETZ Study Group Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax. 2010;65:208-214 [PubMed]journal. [CrossRef] [PubMed]
 
Nowak A. .Breidthardt T. .Christ-Crain M. .Bingisser R. .Meune C. .Tanglay Y. .et al Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia. Chest. 2012;141:974-982 [PubMed]journal. [CrossRef] [PubMed]
 

Figures

Tables

References

Feldman C. .Anderson R. . Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. Chest. 2015;148:523-532 [PubMed]journal. [CrossRef] [PubMed]
 
Mueller C. .Laule-Kilian K. .Scholer A. .Perruchoud A.P. . B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med. 2005;258:391-393 [PubMed]journal. [CrossRef] [PubMed]
 
Christ-Crain M. .Breidthardt T. .Stolz D. .et al Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med. 2008;264:166-176 [PubMed]journal. [CrossRef] [PubMed]
 
Jeong K.Y. .Kim K. .Kim T.Y. .et al Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J. 2011;28:122-127 [PubMed]journal. [CrossRef] [PubMed]
 
Krüger S. .Ewig S. .Kunde J. .Hartmann O. .Suttorp N. .Welte T. . CAPNETZ Study Group Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax. 2010;65:208-214 [PubMed]journal. [CrossRef] [PubMed]
 
Nowak A. .Breidthardt T. .Christ-Crain M. .Bingisser R. .Meune C. .Tanglay Y. .et al Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia. Chest. 2012;141:974-982 [PubMed]journal. [CrossRef] [PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543